Online citations, reference lists, and bibliographies.
← Back to Search

Diagnosis Of Epithelial Mesothelioma Using Tree‐based Regression Analysis And A Minimal Panel Of Antibodies

S. Klebe, Markku Mikael Nurminen, J. Leigh, D. Henderson
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Aims: Immunohistochemistry with panels of antibodies is a standard procedure to distinguish between malignant mesothelioma and metastatic adenocarcinoma. Most studies assess only the sensitivity and specificity for single antibodies, even when the paper concludes by recommending an antibody panel. It was the aim of this study to use a novel statistical approach to identify a minimal panel of antibodies, which would make this distinction in the majority of cases. Methods: Two hundred consecutive cases of pleural malignancy (173 pleural mesotheliomas of epithelial type and 27 cases of secondary adenocarcinoma) were investigated using a standard panel of 12 antibodies (CAM5.2, CK5/6, calretinin, HBME‐1, thrombomodulin, WT‐1, EMA, CEA, CD15, B72.3, BG8, and TTF‐1). Regression and classification tree‐based methods were applied to select the best combination of markers. The modelling procedures used employ successive, hierarchical predictions computed for individual cases to sort them into homogeneous classes. Results: Labelling for calretinin and lack of labelling for BG8 were sufficient for definite correlation with a diagnosis of malignant mesothelioma. CD15 provided further differentiating information in some cases. Conclusion: A panel of three antibodies was sufficient in most cases to diagnose, or to exclude, epithelial mesothelioma. Calretinin exhibits the strongest correlative power of the antibodies tested.
This paper references
10.1159/000333181
Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
M. Barberis (1997)
10.1046/j.1365-2303.2000.00211.x
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis
A. Dejmek (2000)
10.1046/j.1365-2559.2001.01157.x
Combined use of novel epithelial (MOC‐31) and mesothelial (HBME‐1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura
C. González-Lois (2001)
Immunohistochemical phenotype ofmalignantmesothelioma: predictive value of CA125 and HBME-1
AC Bateman (1997)
10.1046/j.1365-2559.2000.00770.x
HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma
Oates (2000)
10.1053/HUPA.2002.128248
Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.
N. Ordóñez (2002)
10.1001/jama.1986.03380070135039
Theoretical Epidemiology: Principles of Occurrence Research in Medicine
S. Greenland (1986)
Value of cytokertin5/6 in distinguishing epithelial mesothelioma of pleura from lung adenocarcinoma
NG Ordonez (1998)
10.1111/j.1440-1827.2007.02080.x
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
K. Kushitani (2007)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1016/0046-8177(90)90036-5
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
M. Wick (1990)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
10.1038/modpathol.3800544
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
10.1038/modpathol.3800543
Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
N. Ordóñez (2006)
10.1002/widm.8
Classification and regression trees
W. Loh (2011)
10.5580/221d
Prognostic Models for Predicting Delayed Onset of Renal Allograft Function
Markku Mikael Nurminen (2003)
Tumors of the serosal membranes
H. Battifora (1995)
10.1016/J.HUMPATH.2006.08.010
What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
N. Ordóñez (2007)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1097/00000478-198604000-00001
Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases
K. Sheibani (1986)
10.2307/2685660
Modern Applied Statistics with S-Plus
Karen Kafadar (1999)
10.1002/path.1312
Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium
M. Gulyás (2003)
10.1016/S0046-8177(98)90227-1
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1111/j.1365-2559.1994.tb00004.x
Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies
B. Skov (1994)
10.1111/j.1365-2559.2005.02331.x
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data
J. King (2006)
10.1111/j.1699-0463.1994.tb04873.x
Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis
A. Dejmek (1994)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1093/AJCP/112.1.75
Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update.
N. Ordóñez (1999)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
L. Dibonito (1993)
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data, Histopathology
JE King (2006)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1002/ijc.22006
Interleukin‐6 induces both cell growth and VEGF production in malignant mesotheliomas
Yasuo Adachi (2006)
10.1046/j.1365-2559.2002.01352.x
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum
R. Attanoos (2002)
10.1111/j.1365-2559.2006.02442.x
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports
J. King (2006)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
Edited by Roggli VL
TA Sporn (2004)
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
D. Jordon (1989)
10.1043/0003-9985(2001)125<1316:IAONVC>2.0.CO;2
Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
M. Foster (2001)
10.1043/1543-2165(2005)129[1407:IDOEMA]2.0.CO;2
Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
N. Ordóñez (2005)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
Tumors of the Serosal Membranes. Washington DC: American Registry of Pathology/Armed Forces Institute of Pathology
A Churg (2006)
10.1097/00000478-199810000-00005
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
N. Ordóñez (1998)
10.1097/00000478-200302000-00002
Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura
M. Miettinen (2003)
10.1097/00000478-200004000-00016
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
N. Ordóñez (2000)
10.1016/s0169-5002(87)80457-9
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
C. Szpak (1986)
10.2307/2530946
Classification and Regression Trees
L. Breiman (1983)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
10.1046/j.1365-2559.1996.d01-562.x
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME‐1 expression
A. Bateman (1997)
Prognostic models for delayed onset of renal allograft function., The internet journal of epidemiology
M Nurminen (2003)
E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma, Histopathology
MP Leers (1998)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1097/00000478-198904000-00003
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
10.1016/s0169-5002(87)80458-0
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
K. Sheibani (1986)
10.1016/0169-5002(94)92126-1
Pathology of malignant mesothelioma.
E. V. Van marck (2004)
Leu-M1 antigen in human neoplasms: An immunohistologic study
K Sheibani (1986)
WTE: Tumors of the Serosal Membranes. Atlas of Tumor Pathology, 3rd series, fascicle 15
H Battifora (1995)
HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast
AA Renshaw (1995)
10.1093/AJCP/109.1.85
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
N. Ordóñez (1998)
Prognostic models for delayed onset of renal allograft function
M. Nurminen (2003)
E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic
MP Leers (1998)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1016/S0046-8177(99)90011-4
The immunohistochemical diagnosis of epithelial mesothelioma.
N. Ordóñez (1999)
10.1111/j.1365-2559.1995.tb01527.x
A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu‐M1, Ber EP4, Tamm‐Horsfall protein and thrombomodulin
R. Attanoos (1995)
10.1007/978-0-387-68792-6
Dail and Hammar's pulmonary pathology
Joseph F. Tomashefski (2008)
The pleura. Edited by Sternberg SS
H Battifora (1989)
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review
J King (2006)
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports, Histopathology
J King (2006)
The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
L. Dibonito (1992)
10.1002/DC.2028
Comparison of antibodies to HBME‐1 and calretinin for the detection of mesothelial cells in effusion cytology
P. Fetsch (2001)
10.1046/j.1365-2559.1997.2150833.x
Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma
J. Clover (1997)
10.1016/J.HUMPATH.2003.11.013
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
10.1177/140349489302100402
Summarization, smoothing, and inference in epidemiologic analysis
S. Greenland (1993)



This paper is referenced by
10.1371/journal.pone.0070940
Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
C. Wright (2013)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.4132/KOREANJPATHOL.2009.43.5.458
Malignant mesothelioma in body fluids - with special reference to differential diagnosis from metastatic adenocarcinoma
J. Paik (2009)
10.1378/chest.12-2356
Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
A. Schwartz (2013)
10.1016/j.prp.2016.07.010
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
V. Ascoli (2016)
10.1038/srep06152
Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma
A. Hudson (2014)
10.1111/ajco.12043
Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review
Anthony Linton (2013)
10.1111/j.1445-5994.2012.02925.x
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia
S. C.-H. Kao (2013)
10.1097/PAT.0b013e32834642da
Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
S. Kao (2011)
10.1007/978-3-642-10862-4_5
Pathohistological diagnosis and differential diagnosis.
I. Tischoff (2011)
10.1002/cncr.26497
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
10.1097/PAT.0B013E328358299A
Is there a need for expert opinion for biopsy diagnosis of difficult cases of malignant mesothelioma?
S. Klebe (2012)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1097/PAT.0b013e3283634025
Endotracheal angiomatoid 'malignant' fibrous histiocytoma: EWSR1 gene rearrangement.
Wenfang Chen (2013)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.1097/PAT.0b013e3283639bba
The usefulness of expert opinion in medicolegal referrals of malignant mesothelioma.
Dani-Louise Dixon (2013)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
10.1700/1660.18182
Expression of Thrombomodulin, Calretinin, Cytokeratin 5/6, D2–40 and WT-1 in a Series of Primary Carcinomas of the Lung: An Immunohistochemical Study in Comparison with Epithelioid Pleural Mesothelioma
C. Comin (2014)
Semantic Scholar Logo Some data provided by SemanticScholar